Oncolytics Biotech Inc ONCY

$0.50 +0.00 (0.42%)

Valuation

Market cap
65,862,000
Revenue TTM
$0
Net income TTM
$-28,760,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
376,000
Avg volume
1,111,374
Day's range
$0.49 – $0.51
Shares out
131,121,000
Stochastic %K
41%
Beta
1.15
Analysts
Strong Sell
Price target
$4.42

Price

Company profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply i...

Show more

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
403 670 7377
Website
https://oncolyticsbiotech.com
Address
4350 Executive Drive, Suite 325, San Diego, United States

Latest news